Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib, Cadonilimab, and PULSAR in Advanced Biliary Tract Cancer
NCT07635290Phase 2Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, cadonilimab in biliary tract cancer (BTC), sponsored by West China Hospital of Sichuan University. Started Jun 2026; status: active, not recruiting.
02
Drugs
anlotinibcadonilimab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07635290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635290.